Congratulations to Daniel Caldeira on your public disclosure, “The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY” #ClinicalResearch https://t.co/Q78T52Y2Ah
あくまでも探索的解析ながら、ダビガトラン群の頭蓋内出血の対ワルファリンHRは0.42 [0.18-0.98]。 https://t.co/1h1NqOy2OF
RT @StrokeAHA_ASA: #BriefReport: In this post-hoc analysis of the RE-LY trial, patients who fell had a higher risk of major bleed and ICH,…
RT @StrokeAHA_ASA: #BriefReport: In this post-hoc analysis of the RE-LY trial, patients who fell had a higher risk of major bleed and ICH,…